I to kliniske forsøg med patienter med komplicerede urinvejsinfektioner (N = 1. 179) havde 52% af de mikrobiologisk evaluerbare Doribax- behandlede patienter komplicerede nedre urinvejsinfektioner, og 48% havde pyelonefritis, 16% af disse var komplicerede.
In two clinical trials of patients with complicated urinary tract infections (N=1179), 52% of microbiologically-evaluable Doribax-treated patients had complicated lower urinary tract infections and 48% had pyelonephritis, of which 16% were complicated.